Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome.

R A Spurrell, C W Thorburn, J Camm, E Sowton, D C Deuchar

Seven patients with normal specialized conduction system and three patients with the Wolff-Parkinson-White (WPW) syndrome were studied using programmed stimulation of the heart before and after the administration of intravenous disopyramide. The principal effect of this drug was to prolong the effective refractory period of the atria and ventricles, and to prolong the effective refractory period of the anomalous pathway in the WPW syndrome. In addition, it prolonged the conduction time in the anomalous pathway in the WPW syndrome. These findings suggest that disopyramide would be a useful and safe drug in the management of certain atrial and ventricular arrhythmias and in the management of the Wolff-Parkinson-White syndrome with atrial fibrillation.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Ishikawa, T., Sumita, S., Kimura, K., Kikuchi, M., Kosuge, M., Endo, T., Sugano, T., Sigemasa, T., Usui, T., Umemura, S. (2000). Sinus node recovery time assessment by the overdrive suppression test employing an intravenous injection of disopyramide phosphate. Europace 2: 54-59 [Abstract]  
• Wilson, R. R., Wallace, A. G. (1983). Disopyramide: Six Years' Experience. ANGIOLOGY 34: 367-374 [Abstract]  
• MORADY, F., SCHEINMAN, M. M., DESAI, J. (1982). Drugs Five Years Later: Disopyramide. ANN INTERN MED 96: 337-343 [Abstract]  
• Singh, B. N. (1978). Rational Basis of Antiarrhythmic Therapy: Clinical Pharmacology of Commonly Used Antiarrhythmic Drugs. ANGIOLOGY 29: 206-242